A 52 week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia

Trial Profile

A 52 week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2005

At a glance

  • Drugs Donepezil (Primary)
  • Indications Dementia; Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top